1. The Impact of L-ascorbic acid 2-phosphate on the in vitro dissolution of BAG/β-TCP/PLCL composites for bone applications
- Author
-
Teittinen, Henriikka, Lääketieteen ja terveysteknologian tiedekunta - Faculty of Medicine and Health Technology, and Tampere University
- Subjects
Bioteknologian ja biolääketieteen tekniikan maisteriohjelma - Master's Programme in Biotechnology and Biomedical Engineering ,in vitro bioactivity ,bioactive glass ,dissolution ,L-ascorbic acid 2-phosphate trisodium salt ,biodegradable polymer ,in vitro -menetelmä ,biotekniikka ,synthetic bone graft ,composite ,bone tissue engineering ,luukudokset ,komposiitit ,biomateriaalit - Abstract
Bone has a remarkable capability to self-repair. However, in some cases the patient may be left with bone defects beyond a critical size which cannot be healed through natural processes alone. In these cases, patients often require reconstructive surgery to support healing. There are multiple limitations affecting current treatment options. Therefore, there is a major clinical need for well performing bone graft substitutes which has led to the development of the field of bone tissue engineering. Bone tissue engineering aims to regenerate viable bone by the use of biomaterials, cellular therapies and/or growth factors. The development of biomaterials for bone tissue engineering is especially important because biomaterials not only facilitate the production of bone but simultaneously provide structural support for tissue regeneration. Bone presents manifold requirements for creating optimal bone grafts. No material alone has been able to fully replicate the properties of bone. Therefore, a composite containing a polymeric matrix and a bioceramic phase provides a promising option for bone tissue engineering applications. Bioactive glasses (BAG) are a group of bioceramics with the ability to stimulate more bone regeneration than any other bioceramic. Also, biomaterial scaffolds releasing bone-growth inducing active agents have been suggested to enhance osteogenic differentiation in vitro and in vivo. Though bone-growth inducing active agents are extensively used in cell cultivation, they have not been widely incorporated into scaffolds. L-ascorbic acid 2-phosphate trisodium salt (AS) is a bone-growth inducing active agent which has been shown to stimulate proliferation and osteogenic differentiation of human osteoblasts and human bone marrow stem cells. In this study, bioabsorbable composites of poly(L-lactide-co-ε-caprolactone) (PLCL), β-tricalcium phosphate (β-TCP) and one of two BAGs; 45S5 or a borosilicate BAG, were synthesized and incorporated with AS. The study focused on assessing the potential of the developed composites for bone applications in vitro. The aim was to study how AS impacts the in vitro dissolution properties of the composites and whether the release of BAG ions and AS from the composites can be controlled to, potentially, enhance osteoinduction. The study was divided into four sub-studies: I) AS stability studies, II) AS release from composites, III) assessment of the impact of AS on the release of BAG ions and degradation of the composite, and IV) bioactivity investigation. This study revealed that AS enhances the release of BAG ions from BAG/β-TCP/PLCL composites. Furthermore, the presence of a bioceramic phase in the composites accelerated the re-lease of AS. The study demonstrated that AS restricts or profoundly delays the formation of hydroxyapatite on the surface of BAG/β-TCP/PLCL composites in vitro. The addition of AS to the composite did not change the surface hydrophilicity of the material, but the overall hydrophilicity of the material significantly increased. The study introduced novel composites that have potential for applications in bone tissue engineering.
- Published
- 2022